Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lampalizumab
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Lampalizumab is an antigen-binding fragment (Fab) of a humanized monoclonal antibody that selectively binds to and inhibits complement factor D, a rate-limiting enzyme in the activation and amplification of the alternative complement pathway. It was developed as a potential treatment for geographic atrophy secondary to age-related macular degeneration. Lampalizumab was investigated in multiple phase 3 clinical trials (Spectri and Chroma), but these studies failed to meet their primary efficacy endpoints, leading to discontinuation of its development for this indication. The drug was originally developed by Tanox and later by Genentech/Roche[1][3][4][5][6].
- Other names
- Anti-complement Factor D antibodyAnti-factor D
02
Targets
CFD (Complement Factor D)
Beyond the preview
Go deeper on lampalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lampalizumab.